E-Book, Englisch, 138 Seiten, eBook
Reihe: Schering Foundation Symposium Proceedings Supplements
Lindenmann / Schleuning Interferon: The Dawn of Recombinant Protein Drugs
1999
ISBN: 978-3-662-03787-4
Verlag: Springer
Format: PDF
Kopierschutz: 1 - PDF Watermark
E-Book, Englisch, 138 Seiten, eBook
Reihe: Schering Foundation Symposium Proceedings Supplements
ISBN: 978-3-662-03787-4
Verlag: Springer
Format: PDF
Kopierschutz: 1 - PDF Watermark
Forty years of Interferon I wish to dedicate this short introduction to the memory of Alick Isaacs (1921-1967), and to that of Sir Christopher Andrewes (1896-1988). Let us go back more than 40 years. In 1956 Isaacs was in charge of the Wodd Influenza Centre. Andrewes was head of the division of bac teriology and virology, and deputy director of the National Institute for Medical Research in London. When researchers are faced with a seemingly new phenomenon, ex planations are easy to come by. These explanations fall into two broad categories: the phenomenon in question is either due to something or to the lack of something. I apologize for the primitive way in which I ex press this, but I am going to give three examples, scattered over 100 years, of what I mean. First example: in 1880 the great French microbiologist Louis Pas teur was involved in work on chicken cholera. He was struck by the following observation: if a suitable chicken broth was inoculated with the bacterium, the organism grew profusely and the liquid became tur bid. If he now freed the fluid, by sedimentation or filtration, from the bulk of the organisms and re-inoculated it with the same bacterium, no growth occurred.
Zielgruppe
Research
Autoren/Hrsg.
Weitere Infos & Material
1 Is There Life Without Interferon?.- 2 What Constitutes Therapeutic Success? The Interferons (1978–1998).- 3 The Prehistory and History of the Uses of Interleukin-2 in Cancer Therapy.- 4 Interferon-?: From Pass Interference to Cytokine Networking.- 5 A Biosemiotic View of Interferon: Toward a Biology of Really Living Organisms.- 6 The Clinical and Social Impact of Beta Interferon: the First Approved Therapy in Multiple Sclerosis.- 7 Closing Discussion.- Previous Volumes Published in this Series.
